The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
13,970
Patients take bempedoic acid 180 mg tablet orally once daily
Patients take matching placebo tablet orally once daily
Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)
The primary efficacy end point was a four-component composite of adjudicated MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, as assessed in a time-to first-event analysis.
Time frame: Up to 68 months
Number of Participants With First Occurrence of Three Component MACE
The first key secondary end point was a three-component MACE, defined as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.
Time frame: Up to 68 months
Number of Participants With First Occurrence of Myocardial Infarction
Number of participants with time to first occurrence of fatal and non-fatal myocardial infarction are presented.
Time frame: Up to 68 months
Number of Participants With Time to First Occurrence of Coronary Revascularization
Number of participants with time to first occurrence of coronary revascularization are presented.
Time frame: Up to 68 months
Number of Participants With Time to First Occurrence of Stroke
Number of participants with time to first occurrence of fatal and non-fatal stroke.
Time frame: Up to 68 months
Number of Participants With Time to Cardiovascular Death
Number of participants with time to cardiovascular death are presented.
Time frame: Up to 68 months
Number of Participants With Time to All-cause Mortality
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Huntsville, Alabama, United States
Unnamed facility
Mobile, Alabama, United States
Unnamed facility
Mobile, Alabama, United States
Unnamed facility
Pell City, Alabama, United States
Unnamed facility
Tuscumbia, Alabama, United States
Unnamed facility
Chandler, Arizona, United States
Unnamed facility
Cottonwood, Arizona, United States
Unnamed facility
Fountain Hills, Arizona, United States
...and 1309 more locations
All-cause mortality is death due to any cause. Number of participants with time to all-cause mortality are presented.
Time frame: Up to 68 months